01 Adoption of Over-the-Counter Continuous Glucose Monitoring Devices The blood glucose monitoring devices market analysis indicates increasing adoption of over-the-counter continuous glucose monitoring systems among individuals who do not use insulin. For example, Abbott's Lingo biosensor is available through more than 3,500 Walmart stores across the U.S., reflecting wider retail accessibility and growing consumer interest in glucose monitoring.
02 Development of Minimally Invasive Glucose Microsensors Development of minimally invasive glucose microsensors is gaining attention as manufacturers seek to reduce discomfort associated with conventional glucose monitoring. These devices use compact sensors to measure glucose levels beneath the skin. Manufacturers are focusing on longer sensor wear periods and simplified application.
01 Supply chain disruptions are expected to have a moderate impact on the blood glucose monitoring devices market share due to shortages of semiconductor chips, glucose sensors, and electronic components. The market is expected to experience a K-shaped recovery as established manufacturers with diversified suppliers can restore production faster. Smaller manufacturers remain vulnerable to component shortages and higher procurement costs. The market is projected to grow at a CAGR of 7.24%. Supply constraints could temporarily reduce growth by 1.5 percentage points to 5.74%. Improved component availability and stable production capacity could support recovery toward 7.24%.
01 The blood glucose monitoring devices market forecasts continued investment in continuous glucose monitoring technologies, sensor development, and manufacturing expansion.
02 Key Investment and Funding Activities in Blood Glucose Monitoring Devices Market, 2025–2026 Company Value (USD) Details Sava Technologies USD 36 Million In October 2026, Sava raised Series B funding led by Ascensia Diabetes Care to expand glucose microsensor manufacturing and support commercialization. Signos Inc. USD 20 Million In May 2026, Signos secured funding from investors including Dexcom and GV to expand its glucose monitoring platform and distribution partnership. Biolinq USD 100 Million In April 2025, Biolinq raised Series C funding led by Alpha Wave Ventures to advance its wearable glucose biosensor toward regulatory approval and commercialization.
01 Expanding Insurance Coverage for Continuous Glucose Monitoring and Use of Bedside Glucose Testing in Critical Care Drives Market Reimbursement policies reduce out-of-pocket expenses and encourage long-term adoption of glucose sensors. For example, U.S. Medicare covers continuous glucose monitors for eligible insulin-treated patients and individuals with a documented history of problematic hypoglycemia. This coverage supports higher device utilization and recurring demand for replacement sensors in diabetes management.Need for bedside glucose testing in critical care units is strengthening demand for hospital-grade blood glucose monitoring devices. According to the American Diabetes Association's 2026 guidelines, patients receiving intravenous insulin typically require glucose monitoring every 30 minutes to 2 hours. This frequent testing requirement supports recurring demand for point-of-care glucose meters and test strips.
01 High Recurring Sensor Replacement Costs and Sensor Accuracy Limitations Restrain Market Adoption The recurring cost of continuous glucose monitoring sensors remains a major restraint for patients without adequate insurance coverage. Unlike conventional glucose meters, continuous monitoring systems require periodic sensor replacement. This increases long-term monitoring expenses and limits affordability in price-sensitive markets. Continuous glucose monitoring devices measure glucose in interstitial fluid rather than directly in the blood. This can cause differences between sensor readings and actual blood glucose levels during rapid glucose changes. Sensor adhesion problems and skin irritation may also affect prolonged use.
01 Development of Longer-Lasting Glucose Sensors and Integration of Multianalyte Biosensors Creates New Market Opportunities Advancements in extended-wear glucose sensors are creating opportunities to improve convenience and reduce sensor replacement frequency. Longer sensor lifespans can lower monitoring interruptions and improve patient adherence. For example, Dexcom's G7 15 Day sensor offers a wear period of 15 days with an additional 12-hour grace period. This technology encourages manufacturers to develop durable sensors with improved stability and reduced replacement requirements.The development of multianalyte biosensors presents opportunities for manufacturers to expand beyond conventional glucose monitoring. These devices are being designed to measure glucose alongside other biomarkers, particularly ketones, through a single wearable sensor. Combined monitoring could help insulin-dependent patients identify metabolic changes without using separate testing devices.